Evidence map›Paper›PMID 36713521›Full record

ArticleFrontiers in oncology2022

Evaluating the local expression pattern of IGF-1R in tumor tissues and the circulating levels of IGF-1, IGFBP-1, and IGFBP-3 in the blood of patients with different primary bone tumors.

Mohammad Amin Vaezi, Amir Reza Eghtedari, Banafsheh Safizadeh, Pegah Babaheidarian, Vahid Salimi, Fatemeh Adjaminezhad-Fard, Sahar Yarahmadi, Alireza Mirzaei, Mahtab Rahbar, Masoumeh Tavakoli-Yaraki

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Mohammad Amin VaeziDepartment of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Amir Reza EghtedariDepartment of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Banafsheh SafizadehDepartment of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Pegah BabaheidarianDepartment of Pathology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Vahid SalimiDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Fatemeh Adjaminezhad-FardDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Sahar YarahmadiDepartment of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Alireza MirzaeiBone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, Iran.
Mahtab RahbarDepartment of Pathology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Masoumeh Tavakoli-YarakiDepartment of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Iran University of Medical Sciences · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The present study tried to provide insights into the expression pattern and diagnostic significance of the IGF-1 axis main mediators in three main primary bone tumor types with different degrees of severity. Methods: The real-time qRT-PCR (to analyze IGF-1R gene expression), the immunohistochemistry (to measure IGF-1R protein), and the ELISA assay (to assess the circulating level of IGF-1, IGFBP-1, and IGFBP-3) were applied to confirm this hypothesis. A total number of 180 bone tissues (90 tumors and 90 noncancerous adjacent tissues) and 120 blood samples drained from 90 patients with bone tumors and 30 healthy controls were enrolled in the study. The association of insulin-like growth factor (IGF)-1 axis expression pattern with the patient's clinical pathological characteristics and tumor aggressive features, the diagnostic and predictive values were assessed for all tumor groups. Results: A significantly elevated level of IGF-1R gene and protein was detected in bone tumors compared to the noncancerous bone tissues that were prominent in osteosarcoma and Ewing sarcoma compared to the GCT group. The positive association of the IGF-1R gene and protein level with tumor grade, metastasis, and recurrence was detected in the osteosarcoma and Ewing sarcoma groups. The circulating level of IGF-1, IGFPB-1, and IGFBP-3 were increased in osteosarcoma and Ewing sarcoma and GCT groups that were correlated significantly to the tumor severity. The ability of the IGF-1 axis to discriminate between bone tumors also malignant and benign tumors was considerable. Discussion: In summary, our data suggested that IGF-1R, IGF-1, IGFBP-1, and IGFBP-3 levels are associated with bone tumor malignancy, metastasis, and recurrence that might serve as biomarkers for osteosarcoma and Ewing sarcoma recurrence.

Indexed as

bone tumorsEwing sarcomagiant cell tumorsinsulin-like growth factor-1 (IGF-1)osteosarcomatumor recurrence

Identifiers

PMID36713521
PMCPMC9880312
OpenAlexW4315797437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.